$49 Billion is the total value of ADAGE CAPITAL PARTNERS GP, L.L.C.'s 951 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AVIR | ATEA PHARMACEUTICALS INC | $104,630,000 | +47.8% | 1,694,419 | 0.0% | 0.21% | +39.0% | |
| ANNX | ANNEXON INC | $28,114,000 | +11.2% | 1,009,830 | 0.0% | 0.06% | +3.6% | |
| MARINUS PHARMACEUTICALS INC | $22,640,000 | +26.9% | 1,462,500 | 0.0% | 0.05% | +17.9% | ||
| RCHG | RECHARGE ACQUISITION CORP | $19,091,000 | -3.9% | 1,950,000 | 0.0% | 0.04% | -9.3% | |
| PRAX | PRAXIS PRECISION MEDICINES I | $13,500,000 | -40.5% | 412,081 | 0.0% | 0.03% | -42.9% | |
| GRTX | GALERA THERAPEUTICS INC | $13,314,000 | -13.8% | 1,509,500 | 0.0% | 0.03% | -20.6% | |
| BLSA | BCLS ACQUISITION CORP | $13,080,000 | -5.1% | 1,237,500 | 0.0% | 0.03% | -10.0% | |
| QURE | UNIQURE NV | $11,792,000 | -6.8% | 350,000 | 0.0% | 0.02% | -14.3% | |
| HLXA | HELIX ACQUISITION CORP | $10,318,000 | -10.3% | 1,011,589 | 0.0% | 0.02% | -16.0% | |
| HSAQ | HEALTH SCIENCES ACQ CORP 2 | $8,952,000 | -12.6% | 800,000 | 0.0% | 0.02% | -18.2% | |
| CERE | CEREVEL THERAPEUTICS HLDNG I | $8,238,000 | -17.2% | 600,000 | 0.0% | 0.02% | -22.7% | |
| BCTG | BCTG ACQUISITION CORP | $6,672,000 | -2.8% | 600,000 | 0.0% | 0.01% | -6.7% | |
| RCUS | ARCUS BIOSCIENCES INC | $7,020,000 | +8.2% | 250,000 | 0.0% | 0.01% | 0.0% | |
| CBAY | CYMABAY THERAPEUTICS INC | $6,583,000 | -20.9% | 1,450,000 | 0.0% | 0.01% | -27.8% | |
| KDMN | KADMON HLDGS INC | $5,835,000 | -6.3% | 1,500,000 | 0.0% | 0.01% | -14.3% | |
| ADES | ADVANCED EMISSIONS SOLUTS IN | $5,225,000 | 0.0% | 950,000 | 0.0% | 0.01% | 0.0% | |
| SPRB | SPRUCE BIOSCIENCES INC | $4,822,000 | -31.7% | 290,511 | 0.0% | 0.01% | -33.3% | |
| AJRD | AEROJET ROCKETDYNE HLDGS INC | $4,226,000 | -11.2% | 90,000 | 0.0% | 0.01% | -10.0% | |
| KYMR | KYMERA THERAPEUTICS INC | $3,886,000 | -37.3% | 100,000 | 0.0% | 0.01% | -42.9% | |
| CFRX | CONTRAFECT CORP | $3,120,000 | -5.0% | 650,000 | 0.0% | 0.01% | -14.3% | |
| APSGWS | APOLLO STRATEGIC GROWTH CAPT*w exp 10/29/202 | $2,459,000 | -33.0% | 1,951,866 | 0.0% | 0.01% | -37.5% | |
| WLL | WHITING PETE CORP NEW | $1,778,000 | +41.8% | 50,164 | 0.0% | 0.00% | +33.3% | |
| RCHGW | RECHARGE ACQUISITION CORP*w exp 10/05/202 | $753,000 | -51.7% | 975,000 | 0.0% | 0.00% | -33.3% | |
| OXYWS | OCCIDENTAL PETE CORP*w exp 08/03/202 | $875,000 | +75.0% | 73,493 | 0.0% | 0.00% | +100.0% | |
| AJAXWS | AJAX I*w exp 10/27/202 | $423,000 | -48.4% | 250,000 | 0.0% | 0.00% | -50.0% | |
| MOGA | MOOG INCcl a | $628,000 | +4.8% | 7,553 | 0.0% | 0.00% | 0.0% | |
| CMTL | COMTECH TELECOMMUNICATIONS C | $460,000 | +20.1% | 18,499 | 0.0% | 0.00% | 0.0% | |
| SPKE | SPARK ENERGY INC | $144,000 | +11.6% | 13,474 | 0.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APPLE INC | 43 | Q3 2023 | 6.0% |
| MICROSOFT CORP | 43 | Q3 2023 | 5.5% |
| AMAZON COM INC | 43 | Q3 2023 | 4.0% |
| BERKSHIRE HATHAWAY INC DEL | 43 | Q3 2023 | 1.3% |
| JPMORGAN CHASE & CO | 43 | Q3 2023 | 1.3% |
| EXXON MOBIL CORP | 43 | Q3 2023 | 1.6% |
| JOHNSON & JOHNSON | 43 | Q3 2023 | 1.2% |
| PROCTER & GAMBLE CO | 43 | Q3 2023 | 1.0% |
| WELLS FARGO CO NEW | 43 | Q3 2023 | 1.6% |
| UNITEDHEALTH GROUP INC | 43 | Q3 2023 | 1.2% |
View ADAGE CAPITAL PARTNERS GP, L.L.C.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | September 11, 2023 | 3,685,625 | 3.8% |
| Verastem, Inc. | August 31, 2023 | 1,300,000 | 5.2% |
| Molecular Templates, Inc. | July 18, 2023 | 4,391,489 | 5.4% |
| ABEONA THERAPEUTICS INC. | July 06, 2023 | 3,249,994 | 15.3% |
| Praxis Precision Medicines, Inc. | June 30, 2023 | 7,930,638 | 6.2% |
| REATA PHARMACEUTICALS INC | June 26, 2023 | 1,730,841 | 5.2% |
| Provention Bio, Inc. | February 21, 2023 | 5,398,825 | 6.0% |
| ADAMS NATURAL RESOURCES FUND, INC. | February 09, 2023 | 1,308,791 | 5.4% |
| Akili, Inc.Sold out | February 09, 2023 | 0 | 0.0% |
| Ambrx Biopharma Inc. | February 09, 2023 | 7,191,037 | 2.7% |
View ADAGE CAPITAL PARTNERS GP, L.L.C.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-11 |
| SC 13G | 2024-02-26 |
| SC 13G | 2024-02-26 |
| SC 13G | 2024-02-23 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-12 |
| SC 13G/A | 2024-02-07 |
| SC 13G/A | 2024-02-07 |
| SC 13G/A | 2024-02-07 |
| SC 13G/A | 2024-02-07 |
View ADAGE CAPITAL PARTNERS GP, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.